haematology
Blood cancers

Bortezomib does not increase treatment costs in myeloma

The use of the proteasome inhibitor bortezomib does not increase overall treatment costs in myeloma compared to previous conventional therapies, a South Australian study has found. An analysis of real-world treatment costs for 70 patients treated with bortezomib in Adelaide since 2012 found that overall expenditure on hospitalisation was no greater than costs for a ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic